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Helicobacterpylori Modulation of Gastric Acid
John Calama
Imperial College School ofMedicine, Hammersmith Hospital, London, United Kingdom
Helicobacter pyloriplays majorcausative roles inpeptic ulcerdisease andgastric cancer. Elevated
acid secretion in patients with duodenal ulcers (DUs) contributes to duodenal injury, and dimin-
ished acid secretion in patients with gastric cancer allows carcinogen-producing bacteria to colo-
nize the stomach. Eradication ofH. pylori normalizes acid secretion both in hyper-secreting DU
patients and hypo-secreting relatives of gastric cancer patients. Therefore, we and others have
asked how H. pylori causes these disparate changes in acid secretion.
H. pylori gastritis more or less restricted to the gastric antrum in DUpatients is associated with
increasedacidsecretion. This isprobably becausegastritis increases release oftheantralacid-stim-
ulating hormone gastrin and diminished mucosal expression ofthe inhibitorypeptide somatostatin.
Bacterial products and inflammatory cytokines including TNFa may cause these changes in
endocrinefunction.
Gastritis involving the gastric corpus tends to diminish acid secretion, probably because bacterial
products and cytokines including IL-1 inhibit parietal cells. Pharmacological inhibition of acid
secretion increases corpus gastritis in H. pylonr-infected subjects, so it is envisaged that gastric
hypo-secretion ofany cause might become self-perpetuating. H. pylori-associated mucosal atrophy
will also contribute to acidhypo-secretion and is more likely in when the diet is high in salt or lack-
ing in antioxidant vitamins.
Data on gastric acid secretion in patients with esophagitis are limited but suggest that acid secre-
tion is normal or slightly diminished. Nevertheless, H. pylori infection may be relevant to the man-
agement of esophagitis because: (i) H. pylori infection increases the pH-elevating effect ofacid
inhibiting drugs; (ii)protonpump inhibitors may increase the tendency ofH. pylori to causeatroph-
ic gastritis; and (iii) successful eradication ofH. pylori is reported to increase the likelihood of
esophagitis developing in patients who had DU disease. Points (ii) and (iii) remain controversial
and more work is clearly required to elucidate the relationship between H. pylori, acid secretion,
gastric mucosa atrophy and esophagitis.
INTRODUCTION
Gastric acid secretion plays an
important role in gastro-esophageal reflux
disease (GERD)b. It recently became
clear thatHelicobacterpylori is an impor-
tant etiological factor in other upper gas-
trointestinal diseases including gastric
and duodenal ulcers and gastric cancer,
and there is evidence that changes in gas-
tric acid secretion caused by the bacteri-
um contribute to the pathogenesis ofthese
diseases. This article will examine the
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evidence, and whether effects ofH. pylori
on gastric physiology are relevant to
GERD. First I will consider the effect of
H. pylori on the endocrine and exocrine
cells of the stomach, then consider how
and why how H. pylori affects acid secre-
tion in differently in different disease
groups. Finally I will ask whether H.
pylori's effects on acid secretion are rele-
vant to the pathogenesis and treatment of
GERD.
EFFECTS OF H. PYLORION GAS-
TRIC CELLS (SEE FIGURE 1)
G-cells
Gastrins are realized from G-cells in
the gastric antrum and proximal duode-
num. They act via the circulation to stimu-
late acid secretion, both by stimulating
parietal cells directly and by releasing his-
tamine from nearby enterochromaffin-like
(ECL)-cells. H. pylori infection elevates
plasma gastrin concentrations under all
conditions studied so far [1].
Products ofH. pylori itself, or inflam-
matory factors from the host might be
responsible. H. pylori's enzyme urease
produces copious ammonia, and diets sup-
plemented with ammonium acetate elevat-
ed circulating gastrin in rats. However, the
salt also causes gastritis, which might have
contributed. However, a urease inhibitor
failed to decrease plasma gastrin levels, so
other H. pylori products might be respon-
sible. The bacterium is reported to produce
N-a-methylhistamine which we find to
release gastrin from G-cells via histamine
H2 receptors [1,2].
H. pylori infection elevates mucosal
expression of cytokines including inter-
leukins (IL) 1 , 6 and 8, tumor necrosis
factor-a (TNFa), interferon-y (INFy) and
platelet activating factor. TNFa releases
gastrin from a variety of preparations,
even in the presence of somatostatin
immuno-blockade. INFy, IL-1,B and IL-8
also release gastrin [1, 3, 4]. Interestingly
the effect ofIL-8 was greatly increased by
the presence of sonicates of H. pylori,
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Figure 1. Effects of H. pylori on the cells of the gastric corpus and antrum. Gastrin
from G-cells (G) stimulates parietal cells (P) to secrete acid by releasing histamine from
enterchromaffin-like cells (ECL). All of these cells are normally restrained by release of
somatostatin (SMS) from D-cells (D). Bacterial products stimulate G-cells but inhibit pari-
etal cells. Inflammatory cytokines including tumor necrosis factor (TNFa), interferon (INFy),
and interleukins 1 (ILl j) and 8 (1L8) influence the various cells as indicated, resulting in
changes in acid secretion which depend on the distribution of gastritisCalam: H. pylori andacid 197
suggesting synergism between bacterial
and inflammatory products.
D-cells
Somatostatin peptides are released
from D-cells in the antrum and corpus and
mediate the majorreflexes that inhibit gas-
trin release and acid secretion. D-cells are
stimulated by luminal acid, fasting, gas-
trin-releasing peptide and by small intesti-
nal peptides such as cholecystokinin.
Patients infected with H. pylori have less
somatostatin peptide, less somatostatin
mRNA and fewer immunoreactive D-cells
in their gastric mucosa [1]. This lack of
somatostatin may explain increases in gas-
trin release and acid secretion in infected
subjects.
It is difficult to measure responses of
gastric D-cells in vivo, but we found that a
three- hour infusion of gastrin-releasing
peptide significantly elevates the somato-
statin content of antral biopsies, showing
that the cells are capable of responding,
but the amount remained well below that
present in uninfected persons [5]. The
mechanism responsible for diminished
somatostatin remains unclearbut we found
that incubation of D-cells with TNFa for
24 hours diminished somatostatin release
[6].
ECL-cells
Histamine is released by ECL-cells in
the gastric mucosa and stimulates acid
secretion via H2 receptors onparietal cells.
It is produced from histidine by histidine
decarboxylase. Mucosal concentrations of
histamine have generally been found to be
diminished in H. pylori gastritis. This
probably reflects diminished synthesis
because mucosal levels of histidine decar-
boxylase are also low.
It is not known how H. pylori dimin-
ishes mucosal synthesis of histamine, but
some possibilities have been identified:
1. Prinz et al. found that IL-1f great-
ly inhibits histamine release from
ECL-cells [7].
2. Stimulation of histamine H3
receptors on ECL-cell inhibits hista-
mine release [8]. Therefore N-a-
methyl histamine produced by H.
pylori [1] might be responsible.
Parietal cells
Effects of G-, D-, and ECL-cells on
acid secretion depend greatly on the num-
ber and responsiveness of parietal cells.
This varies from time to time and from
patient to patient (see below) and seems to
predict disease outcomes. Factors that
affect parietal cell function are:
1. Physiological regulators: More
gastrin and less somatostatin will
tend to increase acid secretion, but
suppression of ECL-cells will tend
to diminish acid secretion.
2. H. pylori products: Cave's group
have identified two H. pylori prod-
ucts that inhibit parietal cells. One
resembles nigericin. The other is a
dimer of 46 kDa subunits whose
gene has been cloned. H. pylori also
produces unusual fatty acids that can
inhibit parietal cells. However H.
pylori is also reported to produce N-
a-methyl histamine, which is an
agnoist of histamine H2 (as well as
H1 and H3) receptors, and we found
that instillation ofN-a-methyl hista-
mine into the gastric lumen of unin-
fected volunteers increased their
acid output [9].
3. Inhibitory cytokines: TNFa and
IL-15, which are upregulated in H.
pylori gastritis, also inhibit parietal
cells [1].
4. Gastric atrophy: It is now recog-
nized that H. pylori is a major cause198 Calam: H. pylori and acid
of gastric atrophy [10], which is a
loss of specialized cells including
parietal cells from the gastric
mucosa and, thus, diminishes acid
secretion.
Overall clinical studies suggest that
the net effect of corpus gastritis is to
decrease acid secretion.
EFFECTS OF H. PYLORION ACID
SECRETION IN PATIENTS
Work in this area shows that H. pylori
impairs inhibitory control of acid secre-
tion, consistent with depletion of somato-
statin, but that the overall effect on acid
secretion varies widely between patient
groups.
Effects ofH. pylori on inhibitory control
ofacidsecretion
H. pylori infection causes defects in
the reflex inhibition of acid secretion that
were previously observed in patients with
duodenal ulcer (DU) disease and are
attributable to the paucity of mucosal
somatostatin.
Basal acid secretion. Eradication of
H. pylori produces a significant fall in
basal acid secretion in DU patients [11,
12], but this has not generally been found
in non-ulcer patients. Perhaps acid secre-
tion in DU patients, who have less corpus
gastritis, reflects changes in hormonal
influences, while in non-ulcer patients an
improvement in corpus gastritis after erad-
ication causes a confounding increase in
acid.
Meal-stimulated acid secretion at a
low intragastric pH. H. pylori impairs
inhibition of peptone-stimulated acid
secretion by a low intragastric pH. The low
pH suppressed acid secretion by greater
than 80 percent in uninfected persons but
by less than 50 percent in infected volun-
teers [13]. Acid secretion stimulated by
neutral peptone was similar in both
groups, indicating thatthe abnormality lies
in the inhibitory pathway.
The inhibitory effect ofantral disten-
sion. Antral distension normally inhibits
pentagastrin-stimulated acid secretion, but
this reflex is also attenuated by H. pylori
infection [1].
The inhibitory effect of cholecys-
tokinin infusion. It was recently found that
CCK infusions inhibit GRP-stimulated
acid secretion less in H. pylori infected
persons [1]. This is consistent with a lack
of cholecystokinin-stimulated somato-
statin release.
Gastrin-releasing peptide-stimulated
acid secretion. Infusions of GRP test
inhibit responses because this peptide
stimulates D-cells as well as G-cells. GRP
stimulates D-cells in the antrum viagastrin
and in the corpus through neural reflexes.
D-cells may also be stimulated by small
intestinal hormones such as CCK which
GRP also releases. Acid secretion stimu-
lated by GRP is elevated about three times
in H. pylori infection, and about six times
in DU persons when compared with unin-
fected controls [12]. H. pylori-related ele-
vations of GRP-stimulated acid secretion
disappears slowly during the first year
after successful eradication.
Effects on acid secretion in different
patient groups
Defective inhibitory control increases
acid secretion under specific circum-
stances, but different patient groups also
show global differences in acid secretion.
These are seen during infusions of GRP,
but are classically measured during infu-
sions of gastrin, pentagastrin or histamine
which stimulate maximal acid output
(MAO).
High acid secretion in patients with
duodenal ulcers. The mean MAO in H.
pylori-infected DU patients is about twice
normal. This abnormality was regarded as
being more or less fixed because MAO
was unchanged one month after eradia-
tion. However, recent studies have shown
that MAO does eventually fall when H.
pylori is eradicated from DU patients [14].
Therefore, the raised MAO in DU patients
seems to be a response to H. pylori infec-Calam: H. pylori andacid 199
tion, which might be mediated by the
trophic effect of gastrin, or some other
growth factor on the corpus mucosa.
Low acid secretion on first infection
and inpatients with gastric cancer. In con-
trast, acid secretion more or less disap-
pears for the first few weeks or months of
H. pylori infection [15], and is markedly
diminished in patients who develop gastric
cancer [16]. Interestingly about halfofthe
first-degree relatives of patients with gas-
tric cancer have diminished acid secretion,
which rises when the infection is eradicat-
ed [17] indicating that low acid secretion
can also be a response to the infection.
Infected patients with low acid secretion
tend to have corpus gastritis, which is
probably responsible.
Intermediate rates ofacidsecretion in
other patient groups, including patients
with esophagitis. Maximal acid output in
infected person without ulcers tends to be
normal or slightly diminished. Few have
measured acid in patients withesophagitis.
A study before H. pylori was discovered
showed that 47 Finnish patients with
GERD had an MAO similar or slightly
below that of Finnish controls. There was
no correlation between acid output and
symptoms or the duration of reflux [18],
so gastro-esophageal reflux disease
(GERD) is regarded as adisorder ofmotil-
ity rather than secretion. However, the
effect of H. pylori infection on responses
to proton pump inhibitors [19], which are
the main medical treatment for esophagi-
tis, may be clinically important, and pro-
vides an important insight into the rela-
tionship between thebacterium and altered
gastric physiology.
WHY DO DIFFERENT PATIENTS
REACT DIFFERENTLY
TOTHE SAME INFECTION?
An individual's acid response to H.
pylori seems to predict complications.
Moreover, the acid response might cause
the outcome; excessive acid ulcerates the
duodenum, while diminished acid allows
overgrowth of carcinogen-producing bac-
teria in the stomach lumen. Therefore,
what determines the acid response is of
interest.
(4..
Duodenal ulcer Gastric cancer
high acid low acid
Figure 2. Distribution of gastritis, acid secretion, and disease outcome in H. pyloni infection.
Involvement of the gastric corpus on first infection and in patients with gastric cancer leads to low
acid secretion. Antrum-predominant gastritis inpatients with duodenal ulcers is associated with acid
hypersecretion. Most other infected patients show an intermediate pattern with near-normal or
slightly diminished acid secretion200 Ca/am: H. pylori and acid
Parietal cell mass. In the past, an indi-
vidual's parietal cell mass and MAO were
regarded as closely related and more-or-
less fixed. It was appreciated that gastric
atrophy produces a parallel fall in both as
parietal cells are lost. However, it is now
appreciated that parietal cells remain but
fail to secrete acid on first infection [15],
and that bacterial products and cytokines
decrease the maximal secretory capacity
ofparietal cells in vitro [20].
Distribution of gastritis (Figure 2).
There is a two-way relationship between
distribution of gastritis and acid output.
The antral predominant gastritis found in
DU patients is associated with hyper-
secretion, while thepangastritis is found in
patients with gastric cancer who secrete
little acid. One direction is that the distrib-
ution of gastritis determines acid output,
depending on whether corpus mucosa is
healthy enough to respond to gastrin.
However, the effect of suppressing acid
with omeprazole suggests that the reverse
also occurs. Omeprazole decreases gastri-
tis and colonization in the antrum while in
the corpus, gastritis increases and colo-
nization increases or stays the same [21].
Therefore, it is possible to envisage a
vicious circle whereby hyposecretion and
corpus gastritis become self-perpetuating.
Gastric atrophy. H. pylori infection
promotes the development ofatrophy [10],
and suppression ofacid secretion withpro-
ton pump inhibitors may accelerate this
process [22], although this remains contro-
versial. Environmental factors associated
with atrophy include lack of antioxidants
vitamins, and a high salt diet.
ECL-cell density. It was recently
reported that DU patients who were all
infected with H. pylori had about three
times as many ECL-cells in their gastric
mucosa as either infected non-ulcer, or
uninfected controls [23]. This raises the
possibility that elevated acid secretion in
DUpatients might be due to excessive his-
tamine release from ECL cells in theirgas-
tric corpus mucosa.
Bacterial strain. There is currently no
evidence to link any particular strain of
bacteria to high or low acid secretion. The
presence of antibodies to cagA protein
have been linked with mucosal atrophy
and gastric carcinoma both of which are
associated with low acid secretion, and
with DU disease, which is associated with
high acid secretion.
THE RELATIONSHIP BETWEEN H.
PYLORI INFECTION, ACID AND
GERD
At present this relationship is poten-
tially important in three respects: 1) Long
term proton pump inhibitor therapy was
reported by Kuipers et al. to increase the
likelihood of gastric mucosal atrophy
developing in patients infected with H.
pylori [22]. However, the validity of this
finding and its clinical relevance remain
highly controversial. 2) H. pylori infection
significantly increases the pH-elevating
effect ofproton pump inhibitors [19]. This
may be due to generation of alkali by the
bacterium's urease or an increase in corpus
gastritis. We find that both H. pylori soni-
cates and IL-1i[ add to the antisecretory
effect of omeprazole on parietal cells in
vitro [24]. 3) German studies suggest that
eradicating H. pylori from DU patients
increases the likelihood of GERD subse-
quently appearing [25]. The initial severi-
ty of corpus gastritis predicted the likeli-
hood of GERD, so an elevation of acid
secretion following cure might have con-
tributed. However weight gain was also
implicated, and it remains unclear whether
the main observation is reproducible.
Points 2) and 3) argue against eradi-
cating H. pylori from patients with GERD,
and clinical studies largely show no
improvement in symptoms when this is
done. However the possibility, however
remote, that proton pump inhibitor therapy
exacerbates H. pylori gastritis persuades
most clinicians to eradicate before long-
term therapy.Calam: H. pylori and acid 201
CONCLUSION
In summary, therefore, there is cur-
rently no evidence that H. pylori-related
changes in acid secretion contribute to the
pathogenesis of GERD, although the data
on the topic are distinctly scanty. Further
research is required to clarify whether H.
pylori should be eradicated prior to long-
term administration of proton pump
inhibitors to patients with GERD. This is
likely to render therapy less effective, but
might protect the stomach from develop-
ing atrophy, although this remains highly
controversial.
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